Identification and development of 2,5-disubstituted oxadiazole as potential candidate for treatment of XDR and MDR tuberculosis

Tuberculosis, the infection on the verge of eradication once, is now a great threat to mankind. Emergence of MDR and XDR-TB synergised with HIV and other immune-compressive diseases have increased the life threatening capacities of the disease. A small molecule has been identified here, which showed potent anti-tubercular activity. The identified hit compound has also been proved active against nearly 25 clinical isolates comparable with isoniazid.

Graphical abstractA substituted oxadizole has been identified and then modified to yield 6e, a potent anti-tubercular agent. The anti-XDR & MDR-TB activity is discussed using 25 different isolates.Figure optionsDownload full-size imageDownload as PowerPoint slideHighlights► Identification of novel tractable molecule by HTS is discussed. ► Analoging of newer chemotype, which has proved potent, is conferred. ► A report discussing antimycobacterial activity of hit compound with 25 clinical isolates. ► “Hit” arrived is easy, inexpensive and fast to synthesise.